As a 25-year veteran of clinical molecular diagnostics, Dr. Andrea Ferreira-Gonzalez has seen many changes in genetic technologies used in the testing laboratory. With the advent of personalized medicine and using multi-gene NGS panels as a laboratory-developed test, Dr. Ferreira-Gonzalez and other experts have agreed to lend their expertise to the design of SeraCare’s reference materials. She and other groups have participated in an interlaboratory test of standardized reference materials for detecting cancer somatic mutations, with results that will be published in the coming months.

As a 25-year veteran of clinical molecular diagnostics, Dr. Andrea Ferreira-Gonzalez has seen many changes in genetic technologies used in the testing laboratory. With the advent of personalized medicine and using multi-gene NGS panels as a laboratory-developed test, Dr. Ferreira-Gonzalez and other experts have agreed to lend their expertise to the design of SeraCare’s reference materials. She and other groups have participated in an interlaboratory test of standardized reference materials for detecting cancer somatic mutations, with results that will be published in the coming months.

The field of circulating tumor DNA analysis (ctDNA, also sometimes called in a larger context “liquid biopsy”) holds great promise for monitoring response to cancer treatment, assisting therapeutic choice, monitoring recurrence, and for pre-cancer screening. As such there is a great amount of assay development and ongoing clinical trials; at ClinicalTrials.gov searching for the term "Circulating DNA" you can find over 180 open clinical trials for a wide range of tumor types and interventions.

“Happy families are all alike; every unhappy family is unhappy in its own way.” I have always thought the opening of Anna Karenina applies for many things beyond familial harmony (or lack thereof). Certainly, in the world of molecular genetic diagnostics, conclusive results are usually obtained for most patients; however, there are times when a final result is more elusive than conclusive. When this occurs, it may seem as though no two challenges are ever the same. The following are real examples – presented in general terms for patient and institutional confidentiality – of difficult, unanticipated, and even bizarre cases I encountered during my time in clinical testing for predisposition to hereditary disease. Each of these situations required extraordinary effort, dedicated time, and additional resources for resolution. At the end of each day, satisfaction came from knowing that another problem solved was another patient helped in making life-altering medical management decisions.

For clinical genomics testing laboratories, validation — and to a certain extent, revalidation — is a fact of life. It’s written into the CAP/CLIA regulations. The regulations say you must validate: Any new FDA-cleared test your lab introduces. Any modifications you make to an FDA-cleared test. Any laboratory-developed (LDT) test not subject to FDA regulation. In the case of the first one, validation means you can replicate the performance specifications determined by the manufacturer of the test. In the second two, however, validation involves determining the performance specifications yourself (in seven areas, as outlined by CLIA). How do you go about testing the accuracy of a test your lab purchased or determining the accuracy of a test your lab designed?

What is Zika? Zika virus (ZIKV) is an arbovirus that was first isolated in 1947 in a rhesus monkey from the Zika forest of Uganda. Until 2007, only 14 human cases were reported. The first large human outbreak occurred in 2007 (Yap Island, Micronesia, Pacific) followed by French Polynesia in 2013 that resulted in more than 30,000 cases. In early 2015, the virus came to international attention due to the outbreak in Brazil. Since then the epidemic has spread to more than 50 countries in the Caribbean, Central, and South America, causing tens of thousands of infections. ZIKV is transmitted to people primarily through the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). These are the same mosquitoes that spread dengue and chikungunya. ZIKV can also be transmitted sexually and during pregnancy from the infected mother to the fetus.

While clinical genomics labs (those running NGS-based laboratory developed tests) are not currently subject to FDA oversight, that doesn’t mean they won’t be someday. The question is, how soon will that day come and, when it does, will your lab be ready?

When you’re in charge of quality control (QC) for a clinical genomics testing laboratory, you know that one word — quality — casts a wide net. For you, quality means (among many other things):

Due to either staff turnover or increased testing demand, your clinical genomics laboratory is expanding. You need your new personnel trained and ready to perform at the same high level as the rest of your staff as soon as possible. You know that the best training programs are guided ones, with samples and workflows similar to those your new staff members will encounter on a day-to-day basis. Are your remnant patient samples up to the task?

Clinical NGS tests may be powerful diagnostic tools for your molecular pathology laboratory, but they remain complex amalgamations of different hardware, reagents, and software systems — often from several different vendors and with different levels of quality. Only one of these critical reagents or systems has to fail or underperform in an assay to cause performance drift. If you don’t catch assay drift quickly enough, it can lead to assay failures such as false positives or unexpected changes to assay performance — such as those that impact limit of detection (LoD). How can your lab protect itself better? Avoid these two common mistakes: